Business Description
Bio-Rad Laboratories Inc
NAICS : 334516
SIC : 3826
1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Description
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.41 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.57 | |||||
| Interest Coverage | 33.26 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.39 | |||||
| Beneish M-Score | -2.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.5 | |||||
| 3-Year EBITDA Growth Rate | 102.2 | |||||
| 3-Year EPS without NRI Growth Rate | 126.5 | |||||
| 3-Year FCF Growth Rate | 51 | |||||
| 3-Year Book Growth Rate | 50.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 8.41 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 5.95 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.01 | |||||
| 9-Day RSI | 58.56 | |||||
| 14-Day RSI | 57.71 | |||||
| 6-1 Month Momentum % | -20.56 | |||||
| 12-1 Month Momentum % | -34.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.3 | |||||
| Quick Ratio | 4.22 | |||||
| Cash Ratio | 3.21 | |||||
| Days Inventory | 178.96 | |||||
| Days Sales Outstanding | 54.79 | |||||
| Days Payable | 43.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 57.05 | |||||
| Operating Margin % | 18.37 | |||||
| Net Margin % | -67.66 | |||||
| ROE % | -16.27 | |||||
| ROA % | -12.15 | |||||
| ROIC % | 2.79 | |||||
| ROC (Joel Greenblatt) % | -206.42 | |||||
| ROCE % | -16.9 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 21.94 | |||||
| PS Ratio | 5.75 | |||||
| PB Ratio | 1.83 | |||||
| Price-to-Tangible-Book | 1.96 | |||||
| Price-to-Free-Cash-Flow | 45.52 | |||||
| Price-to-Operating-Cash-Flow | 34.14 | |||||
| EV-to-EBIT | -6 | |||||
| EV-to-Forward-EBIT | 21.44 | |||||
| EV-to-EBITDA | -6.32 | |||||
| EV-to-Forward-EBITDA | -13.61 | |||||
| EV-to-Revenue | 5.42 | |||||
| EV-to-Forward-Revenue | 5.5 | |||||
| EV-to-FCF | 42.8 | |||||
| Price-to-Projected-FCF | 1.67 | |||||
| Price-to-Median-PS-Value | 1.82 | |||||
| Earnings Yield (Greenblatt) % | -16.67 | |||||
| Forward Rate of Return (Yacktman) % | 21.8 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:BIO
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,870.979 | ||
| EPS (TTM) ($) | -66.32 | ||
| Beta | 0.78 | ||
| Volatility % | 34.16 | ||
| 14-Day RSI | 57.71 | ||
| 14-Day ATR ($) | 17.552444 | ||
| 20-Day SMA ($) | 534.126 | ||
| 12-1 Month Momentum % | -34.73 | ||
| 52-Week Range ($) | 462.61 - 832.7 | ||
| Shares Outstanding (Mil) | 29.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bio-Rad Laboratories Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||